Xenon Pharmaceuticals (Nasdaq:XENE) granted equity inducement awards to four new non-officer employees under Nasdaq Listing Rule 5635(c)(4). The grants include 20,200 share options at $60.30 and 11,850 RSUs, with four-year vesting schedules and 10-year option terms.
Xenon also highlights its lead molecule azetukalner, a KV7 potassium channel opener in Phase 3 trials for epilepsy, MDD, and BPD, plus early-stage KV7 and NaV1.7 pain programs.
The company issued modest inducement awards totaling 20,200 options and 11,850 RSUs at a $60.30 stri...
Analysis
The company issued modest inducement awards totaling 20,200 options and 11,850 RSUs at a $60.30 strike, under its 2025 plan. These standard hires-related grants sit against a backdrop of mixed past reactions and relatively low short positioning.
Key Figures
Inducement share options:20,200 optionsInducement RSUs:11,850 RSUsOption exercise price:$60.30 per share+3 more
6 metrics
Inducement share options20,200 optionsGrants to four new non-officer employees
Inducement RSUs11,850 RSUsGrants to four new non-officer employees
Option exercise price$60.30 per shareEqual to July 1, 2026 closing price
Option vesting schedule4 years25% at 1 year, remaining monthly thereafter
Option term10 yearsInducement share option grants
RSU vesting cadence25% annually over 4 yearsFrom each employee’s start date
"were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted share unitsfinancial
"aggregate of 20,200 share options and 11,850 restricted share units (RSUs)."
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
rsusfinancial
"aggregate of 20,200 share options and 11,850 restricted share units (RSUs)."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
phase 3medical
"azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
phase 1medical
"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain."
Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.
nav1.7medical
"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain."
NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.
VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share options and 11,850 restricted share units (RSUs).All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $60.30 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of July 1, 2026.The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the respective employee’s start date, subject to such employee’s continued service relationship with the Company. Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com
FAQ
What equity inducement grants did Xenon Pharmaceuticals (XENE) announce on July 2, 2026?
Xenon Pharmaceuticals announced equity inducement grants to four new non-officer employees. According to Xenon, these awards total 20,200 share options and 11,850 restricted share units, granted as material inducements to employment under Nasdaq Listing Rule 5635(c)(4), with standard multi-year vesting terms.
What are the key terms of Xenon Pharmaceuticals (XENE) stock options granted on July 1, 2026?
The stock options have an exercise price of $60.30 per share and a 10-year term. According to Xenon, options vest 25% after one year, with the remaining 75% vesting monthly over three years, subject to continued service and the 2025 Inducement Equity Incentive Plan.
How do the RSUs granted by Xenon Pharmaceuticals (XENE) to new employees vest?
The RSUs vest in four equal annual installments over four years. According to Xenon, 25% of the underlying shares vest on each of the first four anniversaries of the employee’s start date, contingent on a continued service relationship and plan and award agreement terms.
Why did Xenon Pharmaceuticals (XENE) use Nasdaq Listing Rule 5635(c)(4) for these equity grants?
The company used Nasdaq Listing Rule 5635(c)(4) to grant equity as an inducement to new hires. According to Xenon, the share options and RSUs were considered material to the employees entering employment and were approved by the board’s Compensation Committee.
What is Xenon Pharmaceuticals’ (XENE) lead drug candidate azetukalner and its development stage?
Azetukalner is Xenon’s lead molecule, a novel KV7 potassium channel opener. According to Xenon, azetukalner is in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), forming a key part of its neuroscience-focused pipeline.
What early-stage programs is Xenon Pharmaceuticals (XENE) advancing beyond azetukalner?
Xenon is developing multiple early-stage potassium and sodium channel modulators. According to Xenon, these include KV7 and NaV1.7 programs in Phase 1 development, targeting potential treatments for pain in addition to its later-stage psychiatric and epilepsy indications.
